List of new purchasing methods for Capmatinib

Introduction: Capmatinib is an anti-cancer drug sold under the brand name Tabrecta, used to treat metastatic non-small cell lung cancer, in which tumors have mutations that cause exon 14 of the MET gene encoding the membrane receptor HGFR to be skipped. When purchasing capmatinib, ensure that the source of the drug is legal and safe, and do not purchase the drug from illegal sources.

A new way to purchase Capmatinib

1. Hospital pharmacies: In areas where Capmatinib is available, pharmacies in some large hospitals may hold the agency rights for , and patients can purchase it at the hospital with a prescription.

2. Online pharmacies: With the development of e-commerce, some legal online pharmacies may also provide capmatinib, but before purchasing, you should ensure that these websites have legal drug sales licenses and verify the source of the drug.

3. Pharmaceutical retail chain stores: Some pharmaceutical retail chain stores may sell capmatinib. You can consult several pharmacies.

4. Regular medical institutions: You can consult regular medical institutions to find out whether capmatinib can be purchased, and also learn about the available versions and prices of capmatinib.

Efficacy of capmatinib in the treatment of lung cancer

In a pivotal, multicenter, non-randomized, open-label, multi-cohort phase II study, in a group of patients (n=97) with MET exon 14 mutations, previously untreated patients The overall objective response rate (ORR) was 68% in (n=28) and 41% in previously treated patients 1 (n=69). The median duration of response (DOR) was 12.6 months in treatment-naïve patients and 9.7 months in previously treated patients. Capmatinib showed good therapeutic effects.

Adverse reactions of capmatinib

In the phase II GEOMETRY study, the most common adverse events of capmatinib were peripheral edema, nausea, vomiting, fatigue, dyspnea, and decreased appetite. 54% of patients interrupted the dose due to adverse reactions such as peripheral edema, increased serum creatinine, nausea or vomiting. 23% of patients had dose reductions due to peripheral edema, elevated alanine aminotransferase (ALT), elevated serum creatinine, and nausea.